Appendix 1

Author Relationships With Industry and Others—ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly

NameEmploymentConsultantSpeaker's BureauOwnership/ Partnership/ PrincipalPersonal ResearchInstitutional, Organizational, or Other Financial BenefitExpert Witness
Wilbert S. AronowNew York Medical College—Clinical Professor of MedicineNoneNoneNoneNoneNoneNone
Jerome L. FlegNational Heart, Lung, and Blood Institute—Medical OfficerNoneNone
  • Bristol-Myers Squibb

NoneNoneNone
Carl J. PepineUniversity of Florida, Division of Cardiovascular Medicine—Professor of Medicine
  • Angioblast–DSMB member

  • Boehringer Ingleheim

  • CV Therapeutics

  • DCRI/The Medicines Company–Interim Analysis Review Committee

  • Forest Pharmaceuticals

  • Indigo

  • NicOx

  • Novartis/Cleveland Clinic DSMB Chair

  • Pfizer

NoneNone
  • Abbott*

  • Baxter*

  • Bioheart*

  • Cardium*

  • NIH/NHLBI*

  • Pfizer*

  • Viron*

  • AstraZeneca*

  • AtCore*

  • Baxter*

  • Boehringer Ingelheim*

  • CV Therapeutics*

  • Cardionet*

  • Daiichi Sankyo*

  • GlaxoSmithKline*

  • Merck*

  • Pfizer*

  • Sanofi-aventis*

  • Schering-Plough*

  • The Medicines Company*

  • Wyeth*

None
Nancy T. ArtinianWayne State University College of Nursing—Professor; Associate Dean for Research; Director of the Center for Health ResearchNoneNoneNoneNoneNoneNone
George BakrisUniversity of Chicago Pritzker School of Medicine—Professor of Medicine; Director, Hypertensive Diseases Unit
  • Abbott

  • Boehringer Ingelheim

  • Daichii Sankyo

  • Forest Pharmaceuticals

  • Gilead

  • GlaxoSmithKline

  • Merck

  • Novartis

  • Takeda

  • Walgreens

  • Forest Pharmaceuticals

  • Novartis

None
  • Forest Pharmaceuticals

  • GlaxoSmithKline

  • Juvenile Diabetes Research Foundation

  • National Institutes of Health (NIDDK)

NoneNone
Alan BrownMidwest Heart Specialists—Medical Director, Midwest Heart Disease Prevention Center
  • Abbott

  • Merck

  • Sanofi-aventis

  • Abbott

  • AstraZeneca*

  • GlaxoSmithKline

  • Merck*

  • Merck Schering-Plough

  • Novartis

  • Pfizer

NoneNoneNoneNone
Keith C. FerdinandAssociation of Black Cardiologists—Chief Science Officer
  • AstraZeneca

  • Merck

  • Pfizer

  • Roche

  • AstraZeneca

None
  • Novartis

NoneNone
Mary Ann ForcieaUniversity of Pennsylvania Health System—Clinical Associate Professor of Medicine
  • National Board of Medical Examiners

NoneNoneNoneNoneNone
William FrishmanNew York Medical College/Westchester Medical Center—Rosenthal Professor; Chairman of Medicine
  • Forest Pharmaceuticals

  • GlaxoSmithKline

  • Pfizer

  • Bristol-Myers Squibb

  • Forest Pharmaceuticals

  • Novartis

  • Pfizer

  • Merck*

NoneNoneNone
Cheryl JaigobinUniversity Health Network, University of Toronto—DoctorNone
  • Boehringer Ingelheim

  • Sanofi-aventis

NoneNoneNoneNone
John B. KostisUMDNJ–Robert Wood Johnson Medical School—Professor of Medicine and Pharmacology; Chairman, Department of Medicine
  • Novartis

  • Pfizer

  • Pharmacopeia

  • Sankyo

  • Forest*

  • Pfizer

NoneNoneNone
  • Arent Fox (legal firm)*

Guiseppe ManciaUniversity of Milano at Bicocca—Professor of Medicine
  • Boehringer Ingelheim

  • Merck

  • Novartis

  • Bayer

  • Boehringer Ingelheim

  • Novartis

  • Servier

NoneNoneNoneNone
Suzanne OparilUniversity of Alabama at Birmingham—Professor Medicine, Physiology and Biophysics; Director, Vascular Biology and Hypertension Program
  • Bristol-Myers Squibb*

  • Daiichi Sankyo*

  • Merck*

  • Novartis*

  • Pfizer*

  • Sanofi-aventis*

  • The Salt Institute*

  • Boehringer Ingelheim

  • Bristol-Myers Squibb

  • Daiichi Sankyo

  • Merck

None
  • Daiichi Sankyo

  • Eisai

  • Forest Laboratories

  • GlaxoSmithKline

  • Merck

  • Novartis

  • Sanofi-aventis

NoneNone
Eduardo OrtizNational Heart, Lung, and Blood Institute—Senior Medical OfficerNoneNoneNoneNoneNoneNone
Efrain ReisinLSUHSC, New Orleans—Professor of Medicine; Chief, Section of Nephrology and Hypertension
  • Forest Research Institute

  • Mission Pharmacal

  • AstraZeneca

NoneNone
  • AstraZeneca*

NoneNone
Michael W. RichWashington University School of Medicine—Professor of MedicineNoneNoneNone
  • Astellas Pharma

  • Bristol-Myers Squibb

  • Sanofi-aventis

NoneNone
Douglas D. SchockenDuke University School of Medicine—Professor of Medicine
  • ARCAS Biopharma

  • AstraZeneca

None
  • Boehringer Ingelheim

  • Novartis

  • Sanofi-aventis

NoneNone
Michael A. WeberState University of New York Downstate College of Medicine—Professor of Medicine
  • Boehringer Ingelheim

  • Bristol-Myers Squibb

  • Daiichi Sankyo

  • Forest Pharmaceuticals

  • Gilead

  • Novartis

  • Takeda Pharmaceuticals

  • Boehringer Ingelheim

  • Bristol-Myers Squibb

  • Daiichi Sankyo

  • Forest Pharmaceuticals

  • GlaxoSmithKline

  • Novartis

  • Sanofi-aventis

NoneNoneNoneNone
Deborah J. WesleyWake Forest University Health Sciences—Cardiology Nurse ManagerNoneNoneNoneNoneNoneNone

This table represents the relationships of committee members with industry and other entities that were reported by authors to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, or ownership of $10,000 or more of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted. ACCF indicates American College of Cardiology Foundation; DSMB, Data and Safety Monitoring Board; NIDDK, National Institute of Diabetes & Digestive & Kidney Diseases; NIH, National Institutes of Health; and NHLBI, National Heart, Lung, and Blood Institute.

  • * Indicates significant relationship.